AngioDynamics (NASDAQ:ANGO) Reaches New 12-Month High – Here’s What Happened

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) hit a new 52-week high during trading on Monday . The stock traded as high as $15.73 and last traded at $15.5250, with a volume of 405873 shares traded. The stock had previously closed at $15.69.

Analysts Set New Price Targets

A number of brokerages have weighed in on ANGO. HC Wainwright lifted their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Canaccord Genuity Group upped their price objective on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Zacks Research lowered AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, AngioDynamics currently has a consensus rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Trading Up 1.7%

The stock has a market capitalization of $659.79 million, a price-to-earnings ratio of -18.31 and a beta of 0.33. The firm has a 50-day moving average of $13.16 and a 200 day moving average of $11.68.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. The company had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts forecast that AngioDynamics, Inc. will post -0.25 EPS for the current year.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the company’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Franklin Resources Inc. grew its holdings in shares of AngioDynamics by 2.3% during the fourth quarter. Franklin Resources Inc. now owns 48,359 shares of the medical instruments supplier’s stock valued at $621,000 after purchasing an additional 1,076 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 1,199 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of AngioDynamics by 5.9% in the 4th quarter. Deutsche Bank AG now owns 35,584 shares of the medical instruments supplier’s stock worth $457,000 after purchasing an additional 1,992 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in AngioDynamics during the 4th quarter valued at approximately $27,000. Finally, Price T Rowe Associates Inc. MD increased its position in AngioDynamics by 5.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 44,298 shares of the medical instruments supplier’s stock worth $569,000 after buying an additional 2,263 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.